Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors

Fig. 2

Kaplan-Meier survival curves of overall survival analysis in (A) patients harboring a T790M mutation at progression, with (N = 25) and without (N = 17) second-line osimertinib; and (B) patients with a T790M mutation detected by rebiopsy (N = 28) or by plasma ddPCR alone (N = 14)

OSI, osimertinib

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us